| Primary |
| Drug Use For Unknown Indication |
41.7% |
| Product Used For Unknown Indication |
26.3% |
| Hypercholesterolaemia |
7.1% |
| Hypertension |
6.3% |
| Dyslipidaemia |
4.1% |
| Type 2 Diabetes Mellitus |
1.9% |
| Hyperlipidaemia |
1.8% |
| Hypertriglyceridaemia |
1.7% |
| Atrial Fibrillation |
1.2% |
| Back Pain |
1.2% |
| Depression |
1.1% |
| Diabetes Mellitus |
1.1% |
| Arrhythmia |
0.9% |
| Hypothyroidism |
0.7% |
| Blood Triglycerides Increased |
0.5% |
| Cerebrovascular Accident Prophylaxis |
0.5% |
| Dementia Alzheimer's Type |
0.5% |
| Osteoporosis |
0.5% |
| Rheumatoid Arthritis |
0.5% |
| Schizophrenia |
0.5% |
|
| Rhabdomyolysis |
15.6% |
| Pulmonary Embolism |
10.7% |
| Transaminases Increased |
7.4% |
| Vomiting |
5.7% |
| Pain |
4.9% |
| Pancreatitis Acute |
4.9% |
| Cytolytic Hepatitis |
4.1% |
| International Normalised Ratio Increased |
4.1% |
| Pyrexia |
4.1% |
| Rash |
4.1% |
| Renal Failure Acute |
4.1% |
| Respiratory Failure |
4.1% |
| Angioedema |
3.3% |
| Cardiac Valve Disease |
3.3% |
| Dizziness |
3.3% |
| Pruritus |
3.3% |
| Renal Failure |
3.3% |
| Somnolence |
3.3% |
| Surgery |
3.3% |
| Tendon Rupture |
3.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
22.5% |
| Product Used For Unknown Indication |
19.5% |
| Hypercholesterolaemia |
13.4% |
| Hypertension |
10.7% |
| Dyslipidaemia |
5.4% |
| Diabetes Mellitus |
4.3% |
| Back Pain |
3.9% |
| Depression |
3.4% |
| Atrial Fibrillation |
3.0% |
| Type 2 Diabetes Mellitus |
2.3% |
| Hypertriglyceridaemia |
1.5% |
| Essential Tremor |
1.3% |
| Hiv Infection |
1.3% |
| Hypopituitarism |
1.3% |
| Osteoporosis |
1.3% |
| Anxiety |
1.1% |
| Asthma |
1.0% |
| Essential Hypertension |
1.0% |
| Rheumatoid Arthritis |
1.0% |
| Breast Cancer |
0.8% |
|
| Rhabdomyolysis |
10.2% |
| Pulmonary Embolism |
9.1% |
| International Normalised Ratio Increased |
8.0% |
| Pruritus |
8.0% |
| Renal Failure Acute |
8.0% |
| Pyrexia |
6.8% |
| Cytolytic Hepatitis |
5.7% |
| Myalgia |
4.5% |
| Organising Pneumonia |
4.5% |
| Pancreatitis Acute |
4.5% |
| Tendon Disorder |
4.5% |
| Transaminases Increased |
4.5% |
| Polymyositis |
3.4% |
| Rash Scarlatiniform |
3.4% |
| Tricuspid Valve Incompetence |
3.4% |
| Haematemesis |
2.3% |
| Haemolytic Anaemia |
2.3% |
| Hyponatraemia |
2.3% |
| Overdose |
2.3% |
| Peripheral Sensory Neuropathy |
2.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
25.1% |
| Product Used For Unknown Indication |
12.6% |
| Hypertension |
12.3% |
| Hypercholesterolaemia |
6.7% |
| Diabetes Mellitus |
5.7% |
| Hiv Infection |
4.9% |
| Dyslipidaemia |
4.5% |
| Pain |
3.5% |
| Type 2 Diabetes Mellitus |
3.3% |
| Prophylaxis |
3.2% |
| Osteoporosis |
2.6% |
| Depression |
2.5% |
| Rheumatoid Arthritis |
2.2% |
| Hyperlipidaemia |
1.7% |
| Hypothyroidism |
1.7% |
| Non-small Cell Lung Cancer |
1.6% |
| Thrombosis Prophylaxis |
1.6% |
| Anxiety |
1.5% |
| Breast Cancer |
1.4% |
| Atrial Fibrillation |
1.4% |
|
| Vomiting |
15.5% |
| Renal Failure Acute |
10.7% |
| Renal Failure |
6.9% |
| Pyrexia |
5.6% |
| Thrombocytopenia |
5.6% |
| Weight Increased |
5.6% |
| Pulmonary Embolism |
5.2% |
| Weight Decreased |
4.7% |
| General Physical Health Deterioration |
4.3% |
| Tachycardia |
4.3% |
| Neutropenia |
3.9% |
| Toxic Skin Eruption |
3.9% |
| Vertigo |
3.9% |
| Somnolence |
3.4% |
| Urticaria |
3.4% |
| Malaise |
3.0% |
| Transaminases Increased |
3.0% |
| Pancytopenia |
2.6% |
| Septic Shock |
2.6% |
| Pancreatitis Acute |
2.1% |
|
| Interacting |
| Drug Use For Unknown Indication |
42.3% |
| Arrhythmia |
7.7% |
| Atrial Fibrillation |
7.7% |
| Dyslipidaemia |
5.8% |
| Depression |
3.8% |
| Diverticulitis |
3.8% |
| Epilepsy |
3.8% |
| Hyperlipidaemia |
3.8% |
| Hyperventilation |
3.8% |
| Osteoarthritis |
3.8% |
| Type 2 Diabetes Mellitus |
3.8% |
| Type V Hyperlipidaemia |
3.8% |
| Alcohol Use |
1.9% |
| Mixed Hyperlipidaemia |
1.9% |
| Thrombosis Prophylaxis |
1.9% |
|
| Rhabdomyolysis |
40.0% |
| International Normalised Ratio Increased |
20.0% |
| Drug Interaction |
10.0% |
| Epilepsy |
10.0% |
| Overdose |
10.0% |
| Renal Failure Acute |
10.0% |
|
